Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram L, Jemal A, et al. World cancer statistics 2020: GLOBOCAN estimates of incidence and mortality for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.
Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guideline from the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723–50. https://doi.org/10.1002/hep.29913.
Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450–62. https://doi.org/10.1056/NEJMra1713263.
Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma treatment from diagnosis to death: the BRIDGE study. Liver Int. 2015;35:2155–66. https://doi.org/10.1111/liv.12818.
Ghanaati H, Mohammadifard M, Mohammadifard M. A review on the application of transarterial chemoembolization (TACE) technique in the treatment of hepatocellular carcinoma. J Fam Med Prim Care. 2021;10:3553–60. https://doi.org/10.4103/jfmpc.jfmpc_2347_20.
Sidaway P. HAIC-FO improves outcomes in HCC. Nat Rev Clin Oncol. 2022;19:150. https://doi.org/10.1038/s41571-022-00599-0.
He M, Li Q, Zou R, Shen JX, Fang WQ, Tan GS, et al. Hepatic arterial infusion of sorafenib plus oxaliplatin, fluorouracil, and leucovorin versus sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5:953–60. https://doi.org/10.1001/jamaoncol.2019.0250.
Zhang Z, Li C, Liao W, Huang Y, Wang ZA. Comparison of immune checkpoint inhibitor sorafenib, TACE, and stereotactic radiosurgery combined with sorafenib plus TACE in advanced hepatocellular carcinoma with portal vein tumor thrombus. Cancers. 2022;14. https://doi.org/10.3390/cancers14153619.
Lencioni R, Llovet JM, Han G, Tak WY, Yang JM, Alfredo G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate-stage HCC: the SPACE trial. J Hepatol. 2016;64:1090–8. https://doi.org/10.1016/j.jhep.2016.01.012.
McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73:4–13. https://doi.org/10.1002/hep.31288.
An C, Zuo M, Li W, Chen Q, Wu P. Invasive hepatocellular carcinoma: transcatheter arterial chemoembolization versus hepatic arterial infusion chemotherapy. Front Oncol. 2021;11:747496. https://doi.org/10.3389/fonc.2021.747496.
An C, Yao W, Zuo M, Li W, Chen Q, Wu P. Pseudocapsular hepatocellular carcinoma: hepatic arterial infusion chemotherapy versus transcatheter arterial chemoembolization. Acad Radiol. 2023. https://doi.org/10.1016/j.acra.2023.06.021.
Kourou K, Exarchos TP, Exarchos KP, Karamouzis MV, Fotiadis DI. Applications of machine learning in cancer prognosis and prediction. Comput Struct Biotechnol J. 2015;13:8–17. https://doi.org/10.1016/j.csbj.2014.11.005.
An C, Yang H, Yu X, Han Z, Cheng Z, Liu F, et al. A health record-based machine learning model for predicting recurrence after microwave ablation of hepatocellular carcinoma. J Hepatocell Carcinoma. 2022;9:671–84. https://doi.org/10.2147/JHC.S358197.
Uche-Anya E, Anyane-Yeboa A, Berzin TM, Ghassemi M, May FP. Artificial intelligence in gastroenterology and hepatology: how to advance clinical practice while ensuring health equity. Gut. 2022;71:1909–15. https://doi.org/10.1136/gutjnl-2021-326271.
Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW. Transparent reporting of multivariate predictive models for individual prognosis or diagnosis (TRIPOD): description and details. Ann Intern Med. 2015;162:W1–73. https://doi.org/10.7326/M14-0698. January 6.
EASL Clinical Practice Guideline: Management of Hepatocellular Carcinoma. J Hepatol2018;69:182-236. Source: https://doi.org/10.1016/j.jhep.2018.03.019.
Cardella JF, Kundu S, Miller DL, Millward SF, Sacks D. Society of Interventional Radiology Clinical Practice Guideline. J Vasc Inter Radio. 2009;20:S189–191. https://doi.org/10.1016/j.jvir.2009.04.035.
Liu W, Wei R, Chen J, Li Y, Pang H, Zhang W, et al. Machine learning-based prognostic prediction and risk stratification of transarterial chemoembolization or intra-arterial chemotherapy for unresectable hepatocellular carcinoma. Eur Radiol. 2024-01-30. https://doi.org/10.1007/s00330-024-10581-2.
Wang K, Tian J, Zheng C, Yang H, Ren J, Liu Y, et al. Interpretable prediction of 3-year all-cause mortality in patients with heart failure due to coronary artery disease based on machine learning and SHAP. Comput Biol Med. 2021;137:104813. https://doi.org/10.1016/j.compbiomed.2021.104813.
Ma M, Liu R, Wen C, Xu W, Xu Z, Wang S, et al. Predicting molecular subtypes of breast cancer and identifying interpretable image features using machine learning algorithms. Eur Radiol. 2022;32:1652–62. https://doi.org/10.1007/s00330-021-08271-4.
Li QJ, He MK, Chen HW, Fang WQ, Zhou WM, Liu X, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for bulky hepatocellular carcinoma: a randomized phase III trial. J Clin Oncol. 2022;40:150–60. https://doi.org/10.1200/JCO.21.00608.
Jin ZC, Zhong BY, Chen JJ, Zhu HD, Sun JH, Yin GW, et al. Real-world efficacy and safety of TACE plus camrelizumab plus apatinib in patients with HCC (CHANCE2211): a propensity score matching study. Eur Radiol. 2023. https://doi.org/10.1007/s00330-023-09754-2.
Johnson PJ, Berhane S, Kagebayashi C, Shinji S, Mabel T, Helen LR, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach – ALBI grading. J Clin Oncol. 2015;33:550–8. https://doi.org/10.1200/JCO.2014.57.9151.
Reig M, Forner A, Rimola J, Joana F, Marta B, Ángeles G, et al. BCLC strategies for prognostic prediction and treatment recommendations: 2022 update. J Hepatol. 2022;76:681–93. https://doi.org/10.1016/j.jhep.2021.11.018.
Song S, Bai M, Li X, Guo S, Yang W, Li C, et al. Early predictive value of circulating biomarkers of sorafenib in advanced hepatocellular carcinoma. Expert Rev Mol Diagn. 2022;22:361–78. https://doi.org/10.1080/14737159.2022.2049248.
Hiraoka A, Ishimaru Y, Kawasaki H, Aibiki T, Okudaira T, Toshimori A, et al. Tumor markers AFP, AFP-L3, and DCP in hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Oncology. 2015;89:167–74. https://doi.org/10.1159/000381808.
Zhou H, Song T. Conversion and maintenance therapy for primary hepatocellular carcinoma. Biosci Trends. 2021;15:155–60. https://doi.org/10.5582/bst.2021.01091.
Fan J, Tang ZY, Yu YQ, Wu ZQ, Ma ZC, Zhou XD, et al. Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma. Dig Surg. 1998;15:674–8. https://doi.org/10.1159/000018676.
Shi F, Lian S, Mai Q, Mo ZQ, Zhuang WH, Cui W, et al. Microwave ablation after downstaging of hepatocellular carcinoma: outcomes were similar to tumors within the Milan criteria. Eur Radiol. 2020;30:2454–62. https://doi.org/10.1007/s00330-019-06604-y.
Binnewies M, Roberts EW, Kersten K, Vincent C, Douglas FF, Miriam M, et al. Understanding the tumor immune microenvironment (TIME) for effective treatment. Nat Med. 2018;24:541–50. https://doi.org/10.1038/s41591-018-0014-x.
Cao J, Su B, Peng R, Tang H, Tu DY, Tang YH, et al. Bioinformatics analysis of immune infiltration and TRIM family genes in hepatocellular carcinoma. J Gastrointest Oncol. 2022;13:1942–58. https://doi.org/10.21037/jgo-22-619.
Liu F, Liu D, Wang K, Xie XH, Su LY, Kuang M, et al. Contrast ultrasound-based deep learning radiomics may optimize treatment for patients with very early or early stage hepatocellular carcinoma. Liver Cancer. 2020;9:397–413. https://doi.org/10.1159/000505694.
Ding W, Wang Z, Liu FY, Cheng ZG, Yu XL, Han ZY, et al. A semantic-informed hybrid machine learning model can optimize treatment decisions for patients with untreated 3-5 cm single HCC. Liver Cancer. 2022;11:256–67. https://doi.org/10.1159/000522123.
